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centration found in the left atrium.7 Were reinnervation to spread
from preexisting ganglia within the donor heart, one would antici-
patc that nerve proliferation would emanate from the right atrium
and other small sites where ganglia are concentrated.
The notion that ehest pain during myocardial ischemia could
originale from the atrial remnant or other ehest Organs is difficult to
accept. If the pain came from the recipient's tissue, then the occur-
rence of pain should have had no relation to markers of donor
reinnervation and no correlation with ischemic cardiac events (the
opposite of our observations).
We appreciate the comments of Dr. Uretsky. His experience rein-
forces the importance of sensory reinnervation after cardiac trans-
plantation.
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ORAL ANTICOAGULANT DRUGS
To Ihr Editor: In his arücle on oral anticoagulant drugs (June 27
issue),1 Hirsh gives an excellent review of this important subject.
\Ve disagree, however, with his Interpretation of the literature on
oral anticoagulant treatment in patients with tissue heart valves and
patients with mechanical-valve prostheses.
With regard to patients with tissue heart valves, the study by
Turpie et al.2 compared two levels of intensity of warfarin therapy.
The authors concluded that the less intense regimen was äs efiective
äs the more intense regimen in preventing embolism. However, the
yearly incidence of major embolisms and minor embolisms äs de-
fined by the authors was 8 percent and 44 percent, respectively.
Even though there was no difference between the two levels of
anticoagulation, the incidence of thromboembolism was unaccepta-
bl\ high in both groups of patients. Althuugh these results led Tur-
pie et al." and Hirsh' to conclude that the less intense regimen was
no less efiective, in our view one may conclude only that both regi-
mens were equally ineffective.
With regard to patients with mechanical prosthetic valves, the
study by Saour et al.,3 in which a regimen with very high intensity
was compared with one with a lower intensity, revealed no differ-
ence between the two treatment groups in the incidence pf throm-
boembolism. A different picture emerges when the level of anticoag-
ulation achieved, rather than the level targeted, is taken into
account: all thromboembolic events occurred when the level was
below the lower limit of the target zone of the high-intensity regi-
men. In other words, the high-intensity regimen offered protection
when the target was achieved. The same holds true for the bleeding
episodes; 9 of the 13 major episodes occurred when the level of
anticoagulation was above the upper limit of the high-intensity
target zone. Since all thromboembolic events and most bleeding
episodes occurred when the actual level of anticoagulation was out-
side the target zone, we conclude that patients with mechanical
prosthetic valves who are given high-intensity anticoagulant drug
treatment receive good protection against thromboembolism, with
little risk, if the anticoagulant effect can be maintained within the
target zone.
With regard to the recent study by Altman et al.,4 in which two
regimens of oral anticoagulant therapy were compared in patients
with mechanical prosthetic valves, it should be noted that all these
patients also received aspirin and dipyridamole. Thus, the results
cannot be compared with those of oral anticoagulant therapy alone.
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To the Editor: In his excellent review of oral anticoagulant thera-
py, Dr. Hirsh briefly discusses the development of methods for
monitoring the prothrombin time during oral anticoagulant therapy
and the present imprecision of such monitoring in this country that
is due to the reluctance of physicians to use an International Nor-
mahzed Ratio (INR) formal for reporting results. To determine how
widespread this reluctance is, we conducted a survey of laboratory
Supervisors at all 103 acute care hospitals in Massachusetts in the
winterof 1990-1991.
Supervisors at 86 percent of the hospitals responded. They were
using nine different preparations of thromboplastin (56 individual
lots) from six companies and 16 different Instruments to monitor
prothrombin time. The International Sensitivity Index (ISI) of
these 56 lots of thromboplastin ranged from 1.89 to 2.74. Ninety-
nine percent of the laboratories reported results in seconds; only
4 percent also reported results in terms of the INR. Two thirds of
respondents indicated they had only a vague understanding or none
of the importance of an ISI or the INR.
This brief survey clearly indicates the widespread failure on the
part of these hospitals to report the results of prothrombin-time
measurements in a meaningful and easily comparable fashion. The
wide Variation in the sensitivity of thromboplastins äs indicated by
the ISI values could result in widely divergent levels of anticoagula-
tion, even if all centers used the recommended therapeutic ränge*
for most indications — 1.3 to 1.5 times the control value. Intensive
educational efforts are needed to change practices in monitoring
oral anticoagulant therapy, at least in Massachusetts.
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Dr. Hirsh replies:
To the Editor: v.d. Meer et al. question my Interpretation of three
studies that compared two levels of oral anticoagulant therapy in
patients with prosthetic heart valves. Specifically, they suggest that
the high-intensity regimen is safe if the prothrombin time is main-
tained in the target zone. This conclusion does not negate the obser-
vation that in all three studies the less intense regimen was äs effec-
tive äs the more intense regimen and resulted in less bleeding.
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The patients with tissue prosthetic heart valves received treat-
ment for three months to cover the high-risk period (this is Standard
practicc). The primary measure of outcome, established a priori,
was the incidence of major embolism over a three-month period —
2 percent in both groups. Extrapolating this figure to an annual
incidence of 8 percent is inappropnate since the risk of embolism in
these patients is limited largely to the initial three months after
Operation. A minor embolism was defined äs any reversible cerebral
event, and in many instances an event may not have been embolic in
nature. The risk of bleeding (including major bleeding) was signifi-
cantly higher m the group given the high-intensitv regimen. On the
basis of these findings (and in the absence of contrary findings), it
would be difficult to justify the use of high-intensity anticoagulant
therapv in patients with tissue prosthetic heart valves.
The poini at issue in the study b\ Saour et al. was not whether
high-intensity therapy might have produced less bleeding if the
target ränge had not been exceeded, but whether the less intense
treatment appeared to be äs effective and safer. The study by Alt-
man et al. merely confirmed the principle that the use of a more
intense regimen in patients with mechanical prosthetic valves pro-
duces more bleeding without obvrous improvement in efficacy.
The results of these and other clinical trials to determine the
optimal therapeutic ränge have challenged our clinical prcjudices.
The onus is now on the proponents of more intense therapy to
demonstrate the superiority of their favored approach.
The survey described by Dr. Ansell emphasizes the sorry state of
the reporting of prothrombin times by participating hospitals in
Massachusetts. Surely, this is an issue that should be addressed by
appropnate medical societies, regulatory agencies, and hospital
quahty-assurance programs.
JACK HIRSH, M.D.
Hamilton Civic Hospitals
Hamihon, ON L8V 1C3, Canada Research Centre
PRESENCE OF THE FRENCH CANADIAN DELETION
IN A FRENCH PATIENT WITH FAMILIAL
HYPERCHOLESTEROLEMIA
To thf Editor: Familial hypercholestcrolemia is an autosomal
dominant disorder due to mutations in the low-density-lipoprotein
(LDL)-receptor gene. In the French Canadian population, 60 per-
cent of patients with familial hypercholesterolemia have the same
large deletion in the 5' region of the LDL-receptor gene (the French
Canadian deletion),1 whereas in most other populations each unre-
lated patient with familial hypercholesterolemia seems to have a
different LDL-receptor mutation.2 The high frequency of the former
deletion makes it a useful tool for early diagnosis of familial hyper-
cholesterolemia in French Canadians. The question arises, how-
ever, whether this mutation is frequent in France, since French
Canadians are descended from French settlers
To answer this question, we studied 72 unrelated patients with
familial hypercholesterolemia, 30 from the Paris area and 42 from
the western part of France (the place of origin of many French
Canadians). Ten micrograms of leukocyte DNA from each patient
was digested with the restriction enzymes' Xba\ and K.pn\ or A'mnl.1
The digested DNA was fractionated on 0.7 percent agarose gels and
transferred to nylon membranes. The membranes were hybridized
with a radiolabeled probe and subjected to autoradiography. The
probe was the exon 2 of the LDL-receptor gene, obtained by poly-
merase-chain-reaction amplification from the full-length LDL-re-
ceptor complementary DNA. The autoradiograms of all patients
revealed one fragment of 9 kb after digestion with Xba\ and Kpnl or
one fragment of 12 kb after digestion with Xbal and A'mnl. One
patient. from the western part of France, had a second fragment, of
19 kb, after digestion with Xbal and A'mnl; this fragment resembled
that found in the French Canadians,3 thus revealmg the presence of
the French Canadian deletion.
This finding Supports the French origin of the French Canadian
deletion. However, it suggests that the high frequency of this muta-
tion among French Canadian patients with hypercholesterolemia is
due to a founder effcct rather than a high frequency in the popula-
tion of origin.
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INTRAUTERINE GROWTH RETARDATION.
PERINATAL DEATH, AND MATERNAL
HOMOCYSTEINE LEVELS
To the Editor: Intrautenne growth retardalion is associated w i t h
atheroma-like lesions in the artenes of the placental bed.1 The find-
ing of incrcased resistance to uterine-artery blood fiow is predictive
of both preeclampsia and mtrautenne growth retardation.2 Hyper-
homocysteinemia has been idcntified äs an important risk factor for
occlusive vascular disease in nonpregnant adults,1 but its cffect on
the uteroplacental vasculature is not known Women with homocys-
tinuna due to cystathionine /3-synthase deficiency may have an
increased incidence of pregnancy loss,"1 and a recent report by
Steegers-Theumssen et al. (April 25 issue)'' suggests that mothers of
babies with neural-tube defects have increased circulatmg homocys-
teme concentrations.
We examined the obstetncal histones of eight women who were
obligate heterozvgotes for homocystmuria. These women had had a
total of 34 pregnancies between 1960 and 1990, 4 (12 percent)
ending in spontaneous abortion. The mean (±SD) birth weight for
the remaming 30 babies was 3408±774 g, which was not significant-
ly different from the value for the general population. Each woman
had one infant with homocystinuna; the mean birth weight of these
eight infants was 3652±574 g. Among the 30 mfants, there were
three perinatal deaths, yielding a high permatal mortahty rate of
100 per 1000. One, who weighed about 750 g, was stillborn. A
second infant with a neural-tube defect (spina bifida) died two
weeks after delivery. The third was an infam delivered at 31 weeks'
gestation, because of severe preeclampsia, to a mother who had had
a previous uncomplicated pregnancy. The baby weighed 1220 g and
died from comphcations of prematurity. In none of these three
infants was a homocystmunc disease confirmed or excluded.
We also measured fasting plasma total homocysteine concentra-
tions in mothers who delivered babies with growth retardation at
the Coombe Lying-In Hospital. Women whose period of gestation
